HomeSBHMY • OTCMKTS
add
Sino Biopharmaceutical Unsponsored Caymand Islands ADR
Previous close
$7.20
Year range
$6.69 - $11.18
Market cap
54.15B HKD
Avg Volume
247.00
Market news
Financials
Income Statement
Revenue
Net income
| (CNY) | Dec 2023info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | — | — |
Net income | — | — |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | — | — |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (CNY) | Dec 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 12.56B | -25.75% |
Total assets | 63.60B | -0.72% |
Total liabilities | 25.43B | -2.63% |
Total equity | 38.17B | — |
Shares outstanding | 18.35B | — |
Price to book | 4.34 | — |
Return on assets | — | — |
Return on capital | — | — |
Cash Flow
Net change in cash
| (CNY) | Dec 2023info | Y/Y change |
|---|---|---|
Net income | — | — |
Cash from operations | — | — |
Cash from investing | — | — |
Cash from financing | — | — |
Net change in cash | — | — |
Free cash flow | — | — |
About
Sino Biopharmaceutical Limited, shortly Sino Biopharm, is a civilian-run enterprise principally engaged in the medicine products business in Mainland China.
Being a member of Charoen Pokphand Group and headquartered in Hong Kong and Beijing, Sino Biopharm is engaged in researching, developing, producing, and selling biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis through its subsidiaries.
Sino Biopharm is also involved in other minor businesses through its subsidiaries, such as properties, health food, optical glass, optical and auditory products. Wikipedia
CEO
Founded
2000
Website
Employees
25,806
